Quick Answer
Sigyn Therapeutics, Inc. reported Diluted EPS of $2.51 per share (loss) for fiscal year 2024.
Sigyn Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2024 | -$2.51 | +33.4% |
| 2023 | -$3.77 | -20.4% |
| 2022 | -$3.13 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.36 | +61.7% | +60.0% |
| June 30, 2025 | -$0.90 | -28.6% | -114.3% |
| March 31, 2025 | -$0.42 | +32.3% | +55.3% |
| September 30, 2024 | -$0.94 | -14.6% | -34.3% |
| June 30, 2024 | -$0.70 | -4.5% | -12.9% |
| March 31, 2024 | -$0.62 | +55.4% | +24.4% |
| September 30, 2023 | -$0.82 | -4000.0% | -22.4% |
| June 30, 2023 | -$0.67 | -3250.0% | +51.8% |
- Sigyn Therapeutics, Inc. showed an increase of +33.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2024 period, Sigyn Therapeutics, Inc.’s diluted eps has grown by 19.8% (from $3.13 per share (loss) to $2.51 per share (loss)).
- The most recent figure is from Sigyn Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: